{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:24:19Z","timestamp":1791599059016,"version":"4.3.4"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Gaucher disease (GD) is caused by deficiency of the lysosomal membrane enzyme glucocerebrosidase (GCase) and the subsequent accumulation of its substrate, glucosylceramide (GC). Mostly missense mutations of the glucocerebrosidase gene (<jats:italic>GBA<\/jats:italic>) cause GCase misfolding and inhibition of proper lysosomal trafficking. The accumulated GC leads to lysosomal dysfunction and impairs the autophagy pathway. GD types 2 and 3 (GD2-3), or the neuronopathic forms, affect not only the Central Nervous System (CNS) but also have severe systemic involvement and progressive bone disease. Enzyme replacement therapy (ERT) successfully treats the hematologic manifestations; however, due to the lack of equal distribution of the recombinant enzyme in different organs, it has no direct impact on the nervous system and has minimal effect on bone involvement. Small molecules have the potential for better tissue distribution. Ambroxol (AMB) is a pharmacologic chaperone that partially recovers the mutated GCase activity and crosses the blood-brain barrier. Eliglustat (EGT) works by inhibiting UDP-glucosylceramide synthase, an enzyme that catalyzes GC biosynthesis, reducing GC influx load into the lysosome. Substrate reduction therapy (SRT) using EGT is associated with improvement in GD bone marrow burden score and bone mineral density parallel with the improvement in hematological parameters. We assessed the effects of EGT and AMB on GCase activity and autophagy-lysosomal pathway (ALP) in primary cell lines derived from patients with GD2-3 and compared to cell lines from healthy controls. We found that EGT, same as AMB, enhanced GCase activity in control cells and that an individualized response, that varied with <jats:italic>GBA<\/jats:italic> mutations, was observed in cells from patients with GD2-3. EGT and AMB enhanced the formation of lysosomal\/late endosomal compartments and improved autophagy, independent of <jats:italic>GBA<\/jats:italic> mutations. Both AMB and EGT increased mitochondrial mass and density in GD2-3 fibroblasts, suggesting enhancement of mitochondrial function by activating the mitochondrial membrane potential. These results demonstrate that EGT and AMB, with different molecular mechanisms of action, enhance GCase activity and improve autophagy-lysosome dynamics and mitochondrial functions.<\/jats:p>","DOI":"10.1371\/journal.pone.0247211","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:29:57Z","timestamp":1635182997000},"page":"e0247211","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6197-8606","authenticated-orcid":true,"given":"Margarita M.","family":"Ivanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kasaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Adewale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaista","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Fikry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armaghan Hafez","family":"Sanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"pone.0247211.ref001","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cbpa.2007.05.035","article-title":"Gaucher disease","volume":"11","author":"TD Butters","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"pone.0247211.ref002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"J Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"pone.0247211.ref003","first-page":"274","article-title":"Pharmacotherapy of Gaucher Disease","volume":"43","author":"LL Bennett","year":"2018","journal-title":"Current and Future Options"},{"key":"pone.0247211.ref004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","article-title":"Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey","volume":"14","author":"IVD Schwartz","year":"2018","journal-title":"Mol Genet Metab Rep"},{"issue":"Suppl 1","key":"pone.0247211.ref005","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"A Zimran","year":"2014","journal-title":"Pediatr Endocrinol Rev"},{"key":"pone.0247211.ref006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"G Parenti","year":"2009","journal-title":"EMBO Mol Med"},{"key":"pone.0247211.ref007","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"MJ Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0247211.ref008","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease","volume":"35","author":"JA Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"pone.0247211.ref009","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"TM Cox","year":"2017","journal-title":"Blood"},{"key":"pone.0247211.ref010","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"SP Sardi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0247211.ref011","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"GH Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"pone.0247211.ref012","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"A Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"pone.0247211.ref013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"A Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"pone.0247211.ref014","doi-asserted-by":"crossref","first-page":"100476","DOI":"10.1016\/j.ymgmr.2019.100476","article-title":"Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"B Charkhand","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"pone.0247211.ref015","first-page":"3750","article-title":"Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines","volume":"10","author":"MM Ivanova","year":"2018","journal-title":"Am J Transl Res"},{"key":"pone.0247211.ref016","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","article-title":"Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism","volume":"84","author":"AE Kopytova","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0247211.ref017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Z Luan","year":"2013","journal-title":"Brain Dev"},{"key":"pone.0247211.ref018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"I Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"pone.0247211.ref019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.200704091","article-title":"Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis","volume":"179","author":"D Halter","year":"2007","journal-title":"J Cell Biol"},{"key":"pone.0247211.ref020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"RJ Tamargo","year":"2012","journal-title":"Mol Genet Metab"},{"key":"pone.0247211.ref021","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/138620708786734244","article-title":"Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening","volume":"11","author":"DJ Urban","year":"2008","journal-title":"Comb Chem High Throughput Screen"},{"key":"pone.0247211.ref022","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"W Zheng","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0247211.ref023","doi-asserted-by":"crossref","first-page":"e101365","DOI":"10.1371\/journal.pone.0101365","article-title":"Automated quantification and integrative analysis of 2D and 3D mitochondrial shape and network properties","volume":"9","author":"J Nikolaisen","year":"2014","journal-title":"PLoS One"},{"key":"pone.0247211.ref024","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"A McNeill","year":"2014","journal-title":"Brain"},{"key":"pone.0247211.ref025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells","volume":"82","author":"G Ambrosi","year":"2015","journal-title":"Neurobiol Dis"},{"key":"pone.0247211.ref026","doi-asserted-by":"crossref","first-page":"e0210617","DOI":"10.1371\/journal.pone.0210617","article-title":"Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases","volume":"14","author":"MM Ivanova","year":"2019","journal-title":"PLoS One"},{"key":"pone.0247211.ref027","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/1673-5374.202934","article-title":"The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson\u2019s disease","volume":"12","author":"KJ Kinghorn","year":"2017","journal-title":"Neural Regen Res"},{"key":"pone.0247211.ref028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/1873-3468.12979","article-title":"Small fluorescent molecules for monitoring autophagic flux","volume":"592","author":"H Iwashita","year":"2018","journal-title":"FEBS Lett"},{"key":"pone.0247211.ref029","doi-asserted-by":"crossref","first-page":"e1005612","DOI":"10.1371\/journal.pcbi.1005612","article-title":"A novel algorithm identifies stress-induced alterations in mitochondrial connectivity and inner membrane structure from confocal images","volume":"13","author":"M Ouellet","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"pone.0247211.ref030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbamcr.2014.11.002","article-title":"Quantitative analysis of mitochondrial morphology and membrane potential in living cells using high-content imaging, machine learning, and morphological binning","volume":"1853","author":"AP Leonard","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"pone.0247211.ref031","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","article-title":"Mitochondrial membrane potential","volume":"552","author":"LD Zorova","year":"2018","journal-title":"Anal Biochem"},{"key":"pone.0247211.ref032","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0033583500005795","article-title":"Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants","volume":"29","author":"VP Skulachev","year":"1996","journal-title":"Q Rev Biophys"},{"key":"pone.0247211.ref033","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"A Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"key":"pone.0247211.ref034","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fcell.2020.00271","article-title":"Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-","volume":"8","author":"TU Han","year":"2020","journal-title":"Associated Parkinson Disease. Front Cell Dev Biol"},{"key":"pone.0247211.ref035","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1098\/rstb.2003.1266","article-title":"The fate and function of glycosphingolipid glucosylceramide","volume":"358","author":"G van Meer","year":"2003","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"pone.0247211.ref036","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development","volume":"32","author":"LM Panicker","year":"2014","journal-title":"Stem Cells"},{"key":"pone.0247211.ref037","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"KA McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"pone.0247211.ref038","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1523\/JNEUROSCI.4527-15.2016","article-title":"A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin","volume":"36","author":"KJ Kinghorn","year":"2016","journal-title":"J Neurosci"},{"key":"pone.0247211.ref039","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits","volume":"19","author":"Y Sun","year":"2010","journal-title":"Hum Mol Genet"},{"key":"pone.0247211.ref040","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","article-title":"Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting","volume":"19","author":"AM Vaccaro","year":"2010","journal-title":"Hum Mol Genet"},{"key":"pone.0247211.ref041","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease\u2014links to Parkinson\u2019s disease","volume":"17","author":"LD Osellame","year":"2013","journal-title":"Cell Metab"},{"key":"pone.0247211.ref042","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/hmg\/ddt468","article-title":"Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration","volume":"23","author":"T Farfel-Becker","year":"2014","journal-title":"Hum Mol Genet"},{"key":"pone.0247211.ref043","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"O Awad","year":"2015","journal-title":"Hum Mol Genet"},{"key":"pone.0247211.ref044","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","author":"J Magalhaes","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0247211.ref045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ceca.2015.10.002","article-title":"A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca(2)(+) release from acidic Ca(2)(+) stores","volume":"58","author":"G Fois","year":"2015","journal-title":"Cell Calcium"},{"key":"pone.0247211.ref046","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/jnc.12672","article-title":"Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons","volume":"129","author":"W Shen","year":"2014","journal-title":"J Neurochem"},{"key":"pone.0247211.ref047","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3858\/emm.2012.44.2.031","article-title":"Neuronal autophagy and neurodegenerative diseases","volume":"44","author":"JH Son","year":"2012","journal-title":"Exp Mol Med"},{"key":"pone.0247211.ref048","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fcell.2019.00179","article-title":"Biomedical Implications of Autophagy in Macromolecule Storage Disorders","volume":"7","author":"AM Palhegyi","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"pone.0247211.ref049","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.3892\/mmr.2017.7580","article-title":"Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl2\/Bax pathway","volume":"16","author":"JF Li","year":"2017","journal-title":"Mol Med Rep"},{"key":"pone.0247211.ref050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"EV Pavlova","year":"2015","journal-title":"J Pathol"},{"key":"pone.0247211.ref051","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041116","article-title":"Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases","volume":"9","author":"M Ivanova","year":"2020","journal-title":"J Clin Med"},{"key":"pone.0247211.ref052","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fnmol.2017.00064","article-title":"Neuronal Mitophagy in Neurodegenerative Diseases","volume":"10","author":"M Martinez-Vicente","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"pone.0247211.ref053","doi-asserted-by":"crossref","DOI":"10.3390\/diseases4040031","article-title":"Mitochondrial Dysfunction in Lysosomal Storage Disorders","volume":"4","author":"M de la Mata","year":"2016","journal-title":"Diseases"},{"key":"pone.0247211.ref054","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","article-title":"Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease","volume":"25","author":"J Magalhaes","year":"2016","journal-title":"Hum Mol Genet"},{"key":"pone.0247211.ref055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JPD-2011-11025","article-title":"Mitochondrial dysfunction in skin fibroblasts from a Parkinson\u2019s disease patient with an alpha-synuclein triplication","volume":"1","author":"SK Mak","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"pone.0247211.ref056","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fnins.2017.00553","article-title":"Mitochondrial Bioenergetics Is Altered in Fibroblasts from Patients with Sporadic Alzheimer\u2019s Disease","volume":"11","author":"MJ Perez","year":"2017","journal-title":"Front Neurosci"},{"key":"pone.0247211.ref057","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12035-012-8245-1","article-title":"Primary skin fibroblasts as a model of Parkinson\u2019s disease","volume":"46","author":"G Auburger","year":"2012","journal-title":"Mol Neurobiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:30:45Z","timestamp":1635183045000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247211"}},"subtitle":[],"editor":[{"given":"Israel","family":"Silman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247211","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}